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Haptoglobin treatment prevents 
cell‑free hemoglobin exacerbated mortality 
in experimental rat sepsis
Christian A. Schaer1,2, Victor Jeger1,2, Thomas Gentinetta3, Donat R. Spahn2, Florence Vallelian1, 
Alain Rudiger4 and Dominik J. Schaer1*  
Sepsis is a dysregulated host response to infection leading to organ dysfunction, organ 
failure, and death. Multiple mechanisms promote hemolysis during sepsis, such as com-
plement activation, disseminated intravascular coagulation, hemolytic pathogens, sep-
sis-induced erythrocyte dysfunction, blood transfusion, and medical procedures with 
extracorporeal circulation (e.g., renal replacement therapy) [1]. Clinical observations 
suggested that hemolysis with increased cell-free hemoglobin (CFHb) in plasma corre-
lated with reduced survival in sepsis patients [2–4]. CFHb is a toxin, which may worsen 
sepsis pathophysiology by nitric oxide depletion, oxidative tissue injury, activation of 
coagulation and innate immune pathways, and as an iron source for pathogens [5]. The 
acute phase protein haptoglobin is the archetypical Hb scavenger in plasma and irrevers-
ibly neutralizes the toxicity of bound Hb [1].
Here, we performed a prospective, randomized, blinded animal study to pro-
vide direct experimental evidence that CFHb exacerbates sepsis mortality and test 
whether haptoglobin administration could revert this potentially detrimental adverse 
effect of hemolysis. For this, we used a fluid resuscitated fecal peritonitis model in 
awake rats that we have characterized in detail earlier (Fig.  1a) [6]. We first vali-
dated an Hb-administration protocol in 36 septic rats randomized to saline, CFHb, 
or Hb–haptoglobin infusion. Three hours after a bolus followed by continuous infu-
sion, the mean total Hb concentrations in plasma were 5.4 μM (SD ± 3.2 μM) in the 
saline group and 30.4 μM (SD ± 17.3 μM) in the Hb group (Fig. 1b). These data con-
firmed that our infusion protocol resulted in plasma concentrations within the range 
of CFHb observed in patients with severe sepsis [2, 4]. Co-administration of human 
plasma-derived haptoglobin prevented Hb’s renal clearance, resulting in higher 
concentrations than in the CFHb group (54.7  μM ± 63.0  μM). We determined the 
fractions of CFHb, Hb–haptoglobin complexes, and heme-protein adducts by size-
exclusion chromatography. CFHb and heme-protein adducts eluting in the albumin 
region remained suppressed when haptoglobin was administered concomitantly with 
CFHb. This confirms that Hb remains stabilized in the Hb–haptoglobin complex for 
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prolonged periods in circulation and that the complex efficiently prevents Hb degra-
dation and heme release from CFHb [7, 8].
In the main study, we randomized 54 septic Wistar rats to treatment with saline, 
CFHb, or Hb–haptoglobin. One animal randomized to the saline group had to be 
excluded from the study, because the intravenous catheter was dislocated during the 
experiment. In addition, five non-septic animals were infused with CFHb to exclude 
acute Hb toxicity in healthy animals. After fecal slurry injection, tachycardia devel-
oped in all treatment groups consistent with a systemic inflammatory response (i.e., 
sepsis) (Fig. 2a). The exact timepoint of animal death was determined based on ECG 
telemetry recordings. The survival data provided evidence for a significantly higher 
mortality in the group of septic rats infused with CFHb compared to the septic ani-
mals infused with only saline (61% versus 12%; p = 0.0066). Co-administration of hap-
toglobin with CFHb improved mortality to 17%, which was not significantly different 
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Fig. 1 Experimental setup and hemoglobin infusion protocol validation. a Setup scheme of the studies: a 
catheter was placed into the jugular vein and a telemetry ECG electrode was placed subcutaneously the day 
before the experiment. On the next day, the animals were randomized to a treatment group. Fecal slurry was 
injected i.p at T0h to induce sepsis. 4 h later, the animals were treated with ceftriaxone and a continuous saline 
infusion was started to provide fluid resuscitation. At the same time (T4h), we administered a bolus followed 
by continuous-rate infusion of saline, Hb or Hb–haptoglobin complexes for 24 h (Hb bolus = 16 mg, Hb 
continuous rate infusion = 15 mg/h, haptoglobin was dosed at an iso-stoichiometric concentration with Hb). 
b Besides the mortality study, we performed a separate study to determine plasma concentration of total Hb 
by spectrophotometry (left panel black symbols, indicated in heme equivalents), and plasma concentrations 
of CFHb, Hb–haptoglobin complex and hemoprotein by size-exclusion chromatography (gray symbols). 
Plasma was collected 3 h after starting the Hb or Hb–haptoglobin infusion (T7h). p  values: * < 0.05, ** < 0.01, 
*** < 0.001, **** < 0.0001
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Previous reports demonstrated that blood transfusion-induced hemolysis caused 
excess mortality in a canine model of S. aureus pneumonia [5]. In the same model, 
administration of a haptoglobin concentrate improved shock, lung injury, and survival, 
suggesting that Hb-scavenging neutralized the adverse effects of CFHb [5]. With our 
model, we now provide direct evidence that purified Hb administered to reach clinically 
relevant plasma concentrations acts as a toxin during hemolysis, mimicking the adverse 
effect of intrinsic hemolysis. Our data collectively suggest that CFHb is a contributor to 
adverse sepsis outcomes and may provide a rationale for therapeutic haptoglobin sup-
plementation as a strategy to improve clinical sepsis management.
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Fig. 2 Mortality studies in septic rats. Septic rats were randomized to treatment with a bolus followed by 
a continuous infusion of saline, Hb, or Hb–haptoglobin over 24 h. All investigators were blinded for the 
treatment group. An additional group of non-septic rats was infused with Hb to exclude toxicity in healthy 
animals. a Heart rate recordings (mean ± S.E.M) during the 48 h experiments. b Kaplan–Meier survival 
curves. Results of the statistical analysis are provided in the table (c). Survival proportions (Kaplan–Meier) 
were compared using a two-tailed Gehan–Breslow–Wilcoxon test. The familywise significance level of 
0.05 was divided by the number of all possible comparisons (n = 6), resulting in a Bonferroni-corrected 
multiple-comparison significance level of 0.00833. [GraphPad Prism software version 8.0 (GraphPad Software, 
San Diego, CA, USA)]. Numbers of dead animals/total animals per group are given in parentheses
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